Join
Live feed
·
PRReleasevia Quantisnow
Revolution Medicines Inc. logo

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

ByQuantisnow·Wall Street's wire, on your screen.
RVMD· Revolution Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVMD (Revolution Medicines Inc.) and more on Quantisnow.